跳至主要内容
临床试验/JPRN-UMIN000015431
JPRN-UMIN000015431已完成2 期

Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. - Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer.

Yokohama City University Medical Center0 个研究点目标入组 34 人开始时间: 2014年11月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
34

研究概览

简要总结

Anticancer Res. 2018 Dec;38(12):6911-6917. doi: 10.21873/anticanres.13068.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.With history of receiving paclitaxel treatment 2.With serious drug allergy 3.With servaral comorbid disease poorly controlled diabetes poorly controlled hypertension liver cirrhosis, liver failure renal failure intestitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema active infectious disease heart failure, myocardial infarction, angina pectoris or ECG abnormalities within 6 months 4.With active anothor cancer 5.With peripheral neuropathy greater than grade2 6.With HBs antigen positive 7.With pregnant or nursing women 8.Cases who physician judged improper to entry this trial

研究者

相似试验